Drug Search Results
More Filters [+]

Irampanel

Alternative Names: irampanel, biir 561 cl
Latest Update: 2014-08-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: AMPA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Irampanel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT02223507

P1

Completed

Healthy Volunteers

2000-09-01

NCT02222961

P1

Completed

Healthy Volunteers

2000-06-01

NCT02222974

P1

Completed

Healthy Volunteers

1999-08-01

Recent News Events

Date

Type

Title